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Aims: To assess variability in systolic blood pressure (SBP) and albuminuria (urinary albumin
creatinine ratio [UACR]) responses in patients with type 2 diabetes mellitus initiating renin
angiotensin aldosterone system (RAAS) inhibition, and to assess the association of response
variability with cardiovascular outcomes.
Material and Methods: We performed an observational cohort study in patients with type
2 diabetes who started RAAS inhibition between 2007 and 2013 (n = 1600). Patients were
identified from general practices in the Netherlands. Individual response in SBP and UACR was
assessed during 15 months’ follow-up. Patients were categorized as: good responders (ΔSBP
<0 mm Hg and ΔUACR <0%); intermediate responders (ΔSBP <0 mm Hg and ΔUACR >0% or
ΔSBP >0 mm Hg and ΔUACR <0%); or poor responders (ΔSBP >0 mm Hg and ΔUACR >0%).
Multivariable Cox regression was performed to test the association between initial RAAS inhi-
bition response and subsequent cardiovascular outcomes.
Results: After starting RAAS inhibition, the mean SBP change was −13.2 mm Hg and the
median UACR was −36.6%, with large between-individual variability, both in SBP [5th to 95th
percentile: 48.5-20] and UACR [5th to 95th percentile: −87.6 to 171.4]. In all, 812 patients
(51%) were good responders, 353 (22%) had a good SBP but poor UACR response, 268 (17%)
had a good UACR but poor SBP response, and 167 patients (10%) were poor responders. Good
responders had a lower risk of cardiovascular events than poor responders (hazard ratio 0.51,
95% confidence interval 0.30-0.86; P = .012).
Conclusions: SBP and UACR response after RAAS inhibition initiation varied between and
within individual patients with type 2 diabetes treated in primary care. Poor responders had
the highest risk of cardiovascular events, therefore, more efforts are needed to develop person-
alized treatment plans for these patients.
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1 | INTRODUCTION
The cornerstone of treatment to reduce cardiovascular and kidney
complications in patients with type 2 diabetes mellitus is blockade of
the renin angiotensin aldosterone system (RAAS), typically with
angiotensin-converting enzyme (ACE) inhibitors or angiotensin II
receptor blockers (ARBs). In accordance with clinical treatment guide-
lines, RAAS inhibitors are started with a focus on blood pressure
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reduction and not necessarily albuminuria reduction1; however,
reductions in albuminuria during RAAS inhibitor treatment have been
shown to be independent predictors of cardiovascular outcomes.2–4
Parallel reductions in both blood pressure and albuminuria are
suggested to confer the most cardioprotection,5 but patients can also
have a systolic blood pressure (SBP) reduction without a simulta-
neous reduction in albuminuria or vice versa.6–8 While this discor-
dance in response to RAAS inhibition has been documented in
clinical trials, it is not known whether it carries over to the population
treated in clinical practice or what the effect of this individual vari-
ability in response is on cardiovascular risk. Gaining insight into these
responses may help us understand why some patients in clinical prac-
tice do not benefit from guideline-recommended therapy.
The aims of the present study, therefore, were to investigate the
variability in response with regard to SBP and albuminuria after RAAS
inhibition initiation in primary care patients with type 2 diabetes and
to assess whether the differences in response affected cardiovascular
outcomes.
2 | MATERIALS AND METHODS
2.1 | Study design and population
We conducted a cohort study among primary care patients with type
2 diabetes enrolled in the Groningen Initiative to Analyse Type 2 diabe-
tes Treatment (GIANTT) cohort to assess variability in SBP and urinary
albumin creatinine ratio (UACR) response to RAAS inhibition, as well as
the occurrence of cardiovascular events. Only patients who had both
an SBP and a UACR measurement before and after RAAS inhibition
were included in the analysis. Patients were included if they initiated
guideline-recommended RAAS inhibition treatment between January
1, 2007 and July 31, 2013. Initiation with direct renin inhibitors or min-
eralocorticoid receptor antagonists was not included, because these
are not recommended for treatment of patients with type 2 diabetes
with hypertension and/or microalbuminuria. The starting date of the
first RAAS inhibition prescription was defined as the index date. The
follow-up period for response in SBP and UACR was set between
1 and 15 months after the index date. Patients were followed for car-
diovascular events until they left the GIANTT cohort or until the last
data extraction from GIANTT, whichever came first.
The following patient exclusion criteria were applied: a RAAS
inhibitor prescription <730 days before the index date; insufficient
medical record history to assess previous RAAS inhibitor prescription;
concurrent initiation of other antihypertensive agents at index date;
diagnosis with type 2 diabetes >365 days after the index date; a
follow-up period of <1.5 years; incomplete prescription data during
follow-up; insufficient medication adherence to RAAS inhibition,
defined as a medication refill adherence of <75% in the first
15 months and/or a continuous measurement of gaps of >0.25 over
the total follow-up period9–11; no UACR or UACR measurement
below detection limit (<0.26 mg/mmol) and/or no SBP measurement
within 15 months before the index date; no UACR and/or SBP mea-
surement between 1 and 15 months after the index date; and
>365 days difference between the UACR and SBP measurements
after the index date (Figure 1). Medication refill adherence was calcu-
lated as the number of days’ supply in the study period divided by
the total number of days in the study period multiplied by 100. Con-
tinuous measurement of gaps was the total days of treatment gaps
divided by the total days in the study period.
2.2 | Data collection and definitions
Data were retrieved from the GIANTT database, which contains
anonymous longitudinal data collected from general practice elec-
tronic medical records of >50 000 patients with type 2 diabetes reg-
istered in ~200 general practices in the north of the Netherlands.
These electronic medical records include all general practice prescrip-
tions, patient demographics, physical examinations, laboratory mea-
surements, diagnoses as recorded in routine practice and previous
cardiovascular, cerebrovascular and peripherovascular events.12
The most recent SBP and UACR measurements before or at the
index date were taken as the baseline measurements. As the out-
come measurements, we used the first UACR measurement between
1 and 15 months after the index date, and the SBP measurement
closest in time to this UACR measurement. This time window was
used to ensure that the RAAS inhibition treatment effect was fully
present and because Dutch primary practice guidelines recommend
annual UACR measurements. The response in SBP was calculated as
the absolute difference in mm Hg, and the response in albuminuria
was defined as the percent change in UACR between baseline and
outcome measurement. Four response groups were formed using
previously defined thresholds.7,8 Patients were defined as good
responders if there was a reduction in both SBP and UACR (change
in SBP <0 mm Hg and change in UACR <0%). Patients were defined
as intermediate responders if there was decrease in only one variable
(only SBP reduction: change in SBP <0 mm Hg and change in UACR
≥0%; or only UACR reduction: change in SBP ≥0 mm Hg and change
in UACR <0%). If there was no decrease in SBP nor UACR, patients
were defined as poor responders (change in SBP ≥0 mm Hg and
change in UACR ≥0%). Variability within a patient and between
patients was investigated. Within-patient variability was defined as
the patient not having a similar response to the medication in both
SBP and UACR. Between-patient variability was defined as the
SBP & UACR
Before







0 to 15 months 1 to 15 months
Max 1.5 years
FIGURE 1 Timeline of study. RAASi, renin
angiotensin aldosterone system inhibition;
SBP, systolic blood pressure; UACR,
urinary albumin creatinine ratio
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difference in SBP response between patients and the difference in
UACR response between patients.
Differences in cardiovascular outcome between response groups
were investigated using a composite of the following outcomes:
occurrence of ischaemic heart disease or myocardial infarction
>4 weeks previously, and percutaneous transluminal coronary angio-
plasty, coronary artery bypass surgery, and cerebrovascular outcome
including transient ischaemic attack, or cerebrovascular accident, as
documented in the medical records. Mortality data were not available
for this analysis.
2.3 | Statistical analysis
Descriptive data are presented as mean (SD), median (25th to 75th
percentile) for skewed variables, or number (%) for proportions. His-
tograms and scatterplots were constructed to detect outliers. The
natural logarithm of UACR was used for all analyses to account for its
non-normal distribution. Pearson's correlation between SBP and
UACR response was tested. Patient characteristics were compared
among the RAAS inhibition response groups using 1-way ANOVA or
the χ2 test as appropriate. For pairwise comparisons among 4 groups,
2-tailed Bonferroni corrected P values <.01 were considered signifi-
cant. In addition, stratified analyses were performed to assess the
influence of covariates on the distribution in response groups. This
included analyses according to: (1) initiation on an ACE inhibitor or an
ARB; (2) defined daily doses <1 or ≥1 daily defined doses of the initial
prescription; (3) baseline estimated glomerular filtration rate (eGFR)
<60 or ≥60 mL/min/1.73 m2; (4) baseline albuminuria (UACR <3.5 or
≥3.5 mg/mmol); (5) baseline SBP level (SBP <140 or ≥140 mm Hg);
and (6) time between baseline and outcome measurement (<1 year or
≥1 year).
A Cox proportional hazards regression analysis was performed
to assess the association between response groups and cardiovascu-
lar outcomes, adjusting for sex, baseline age, SBP, UACR, glycated
haemoglobin, eGFR and cardiovascular and peripheral vascular mor-
bidity. For patients who experienced >1 event during follow-up,
time to the first event was used for analysis. Two-tailed P values
<.05 were considered significant. Sensitivity analyses were per-
formed including only patients with a baseline UACR ≥3.5 mg/mmol,
only patients with a baseline SBP ≥140 mm Hg, and with UACR
response defined as a >30% instead of >0% decrease. All analyses
were performed with STATA version 13. No imputation of missing
data was performed because data were missing in <5% of the
included patients.
3 | RESULTS
A total of 1600 patients with type 2 diabetes initiating RAAS inhibi-
tion treatment were included from the overall GIANTT cohort
(Figure 2). The patients’ mean (SD) age was 64.9 (10.9) years and
56.4% were male (Table 1). The mean (SD) baseline SBP was 157.1
(20.7) mm Hg. The median (25th to 75th percentile) baseline UACR
was 1.6 (0.8-4.1) mg/mmol. When comparing characteristics of
included patients (n = 1600) with all patients who initiated RAAS
inhibition treatment in this cohort (n = 7755), baseline characteristics
were essentially similar (Table S1).
3.1 | Response and response groups
The mean SBP decrease after a median of 6.7 months after RAAS
inhibition initiation was −13.2 mm Hg and the median UACR reduc-
tion during the same time interval after RAAS inhibition initiation was
−36.6%. There was a large between-individual variability in response
in both SBP (5th to 95th percentile −48.5 to 20) and UACR (5th to
95th percentile −87.6 to 171.4). With regard to within-individual SBP
and UACR responses, a response in both SBP and UACR (good
responders) was observed in 51% of patients, while 10% had no
reduction in both SBP and UACR (Table 2). A total of 22.1% patients
had a reduction in SBP without UACR reduction, and 16.8% of
patients had a reduction in UACR without SBP reduction (Table 2).
SBP response showed a weak correlation (r = 0.06) with UACR
response (Figure 3).
Good responders and SBP-only responders had significantly
higher blood pressure compared with UACR-only and poor
responders at baseline (Table 1). Good responders and UACR-only
responders had higher albuminuria at baseline compared with SBP-
only and poor responders (Table 1). More poor responders and
UACR-only responders had a history of cardiovascular and periph-
eral vascular morbidity. The stratified analysis also showed that the
proportion of good responders in both SBP and UACR was higher
in patients with a baseline SBP ≥140 mm Hg and baseline UACR
≥3.5 mg/mmol, respectively (Table S2). The distribution in response
groups remained similar when stratified for ACE inhibitor or ARB
use, dose <1 or ≥1 defined daily doses, eGFR <60 or ≥60 mL/
min/1.73 m2, and time between measurement <1 year or ≥1 year
(Table S2).
3.2 | Cardiovascular outcomes
During a median (25th to 75th percentile) follow-up time of 4.4 (3.2-
5.7) years, 128 cardiovascular events occurred. After adjustment for
multiple cardiovascular risk markers, being a good responder to both
SBP and UACR was associated with a significantly lower risk of car-
diovascular events compared with being a poor responder in both
variables (adjusted hazard ratio [HR] 0.51, 95% CI 0.30 to 0.86;
P = .012 [Table 3]). SBP-only responders also had significantly lower
risk of cardiovascular events compared with poor responders
(adjusted HR 0.48, 95% CI 0.26-0.88; P = .018 [Table 3]).
Sensitivity analysis including only patients with a baseline SBP
≥140 mm Hg, showed similar results (Table S3). Including only
patients with a baseline UACR ≥3.5 mg/mmol, also showed that good
responders had fewer cardiovascular events than poor responders
(Table S3). Although the point estimate of the HR for the SBP-only
responders remained similar, the association lost significance because
of the smaller number of included patients. Also no changes were
seen regarding the HR for the UACR-only responders (Table S3).
Finally, a sensitivity analysis in which UACR response was defined as
a reduction in UACR ≥30% had similar results to those of our main
analysis (Table S3).
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4 | DISCUSSION
The present study showed that there was large between- and within-
patient variability in blood pressure and albuminuria response after
RAAS inhibition initiation in patients with type 2 diabetes treated in
primary care. In the present cohort, who mostly had elevated blood
pressure levels and normoalbuminuria, a good response in both SBP
and UACR was observed in 51% of patients, while 10% were poor
responders. An intermediate response (response in either SBP or
UACR) was observed in 39% of the patients. Despite having poorer
baseline SBP and UACR levels, good responders and SBP-only
responders had a lower risk of cardiovascular outcomes compared
with poor responders.
Clinical trial data have shown that there is large variability in
response to RAAS inhibition, and that SBP and UACR response may
not always run in parallel within a patient.7,8 The present study is the
first to show similar discordance between SBP and UACR in a “real-
world” population, which is highly relevant for clinical practice.
Randomized controlled trials have included patients with nephropa-
thy and microalbuminuria or worse, but in our “real-life” cohort the
majority of the patients with type 2 diabetes had normoalbuminuria.
While SBP and UACR are independent predictors of cardiovascular
and renal outcomes,2–4 a parallel good response in both SBP and
UACR appears best for cardiovascular and renal protection.5 Our
finding that 39% of patients respond in only one variable is similar to
the results in the clinical trial populations, including the 39% in the
RENAAL trial and 44% in the IRMA-2 trial.7,8 This indicates that the
variability in response to RAAS inhibition seen in clinical trials is also
relevant in primary care.
Previously, it has been suggested that differences in tissue pene-
tration and RAAS activity could explain the difference in albuminuria
and SBP response within individuals.5 The albuminuria response is
thought to depend on intra-renal RAAS inhibition, while the SBP
response may depend on systemic vascular RAAS blockade.13 Aside
from different pharmacological pathways, it is possible that there are
other explanations for the observed response variation. One relevant
Overall GIANTT Database
N=50019
n = 37816  No DM or no RAAS within 730 days before IDX
n = 2826 False starters 
n = 941 DM dx after RAASi
n = 681  Incomplete prescription data
≥ 75% MRA
n = 5242








n = 981  < 75% MRA
n = 294 CMG > 0.25
n = 413 Difference between UACR/SBP and IDX >450 days  
or >365 days difference between UACR/SBP measurement 
n = 101 Baseline SBP / UARC >15 months before IDX 
n = 1532  Follow-up < 548 days
n = 248  Baseline UACR below detection
n = 2445  No UACR and/or SBP measurement before IDX
n = 141 No UACR and/or SBP measurement after IDX
UCAR / SBP before & after 
IDX
n = 2362
Concurrent UCAR / SBP 
measurements
n = 1848
FIGURE 2 Selection of analysed
population. GIANTT, Groningen Initiative
to Analyse Type 2 diabetes Treatment;
RAASi, renin angiotensin aldosterone
system inhibition; SBP, systolic blood
pressure; UACR, urinary albumin creatinine
ratio
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finding was the difference in baseline variables and drug use between
response groups. In particular, there were significant differences in
baseline SBP and UACR, which could suggest that the observed
responses were partly attributable to differences in room for
improvement or possibly to regression to the mean. Our stratified
analyses, however, showed that there were also substantial groups
with good and intermediate response among patients with low SBP
or low UACR baseline levels. Moreover, approximately 1 in 5 patients
with high SBP or high UACR baseline levels showed no improvement
in these respective measures, suggesting that other, as yet undeter-
mined, factors could be involved.
When examining the associations between response groups and
cardiovascular outcomes, we adjusted for baseline SBP and UACR
levels, history of cardiovascular morbidity, as well as other possible
confounders. These adjustments slightly attenuated the risk estimates
but did not affect the finding that good responders for both SBP and
UACR were at lower risk of cardiovascular events than poor
responders. This finding suggests that SBP and UACR response
should be monitored after ACE inhibitor or ARB initiation to predict
cardiovascular risk. Accordingly, clinical practice guidelines recom-
mend that blood pressure be monitored after initiation of RAAS
inhibition. With respect to albuminuria however, primary practice












ΔSBP <0 mm Hg
ΔUACR ≥0%
ΔSBP <0 mm Hg
ΔUACR <0%
ΔSBP ≥0 mm Hg
ΔUACR ≥0%
ΔSBP ≥0 mm Hg
Age, years 64.9  10.9 64.3  10.7 64.7  11.3 66.1  11.0 66.3  10.1
Men, n (%) 903 (56.4) 446 (54.9) 196 (55.5) 157 (58.6) 104 (62.3)
HbA1c, mmol/mol 52.1  11.3 52.6  12.5 51.6  10.3 52.1  10.3 51.0  8.36
SBP, mm Hg 157.1  20.7 161.9  19.6ab 162.8  18.6ce 143.0  17.8ae 144.4  18.9bc
DBP, mm Hg 85.8  11.0 87.7  10.8ab 87.1  10.3ce 81.2  10.9ae 81.1  10.4bc
UACR, mg/mmol 1.6 [0.8-4.1] 1.8 [0.9-4.8]abd 0.9 [0.5-2.1]cde 2.7 [1.2-7.3]aef 1.2 [0.6-3.4]bcf
Normoalbuminuria, n (%) 1141 (71.3) 560 (69.0) 297 (84.1) 158 (59.0) 126 (75.4)
Microalbuminuria, n (%) 390 (24.4) 211 (26.0) 52 (14.7) 91 (33.9) 36 (21.6)
Macroalbuminuria, n (%) 69 (4.3) 41 (5.0) 4 (1.1) 19 (7.1) 5 (3.0)
eGFR, mL/min/1.73 m2 78.5  18.3 79.2  17.9 78.5  18.5 77.4  18.8 76.8  18.6
Total cholesterol, mmol/L 4.6  1.1 4.6  1.1 4.5  1.1 4.6  1.0 4.5  1.1
HDL cholesterol, mmol/L 1.2  0.3 1.2  0.3 1.2  0.4 1.2  0.3 1.2  0.3
BMI, kg/m2 30.1  5.5 30.3  5.7 29.9  5.6 29.4  4.6 30.1  5.5
ACE inhibitor treatment, n (%) 1307 (81.7) 664 (81.8) 289 (81.9) 223 (83.2) 131 (78.4)
ARB treatment, n (%) 293 (18.3) 148 (18.2) 64 (18.1) 45 (16.8) 36 (21.6)
Cardiovascular morbidity, n (%) 252 (15.8) 99 (12.2)ab 52 (14.7)ce 64 (23.9)ae 37 (22.2)bc
Peripheral vascular morbidity, n (%) 232 (14.5) 113 (13.9)a 42 (11.9)e 53 (19.8)ae 24 (14.4)
Nephropathy, n (%) 71 (4.4) 38 (4.7) 11 (3.1) 14 (5.2) 8 (4.8)
Retinopathy, n (%) 44 (2.8) 24 (3.0) 12 (3.4) 7 (2.6) 1 (0.6)
Diabetes duration, years 5.0  4.9 4.9  5.0 5.0  4.6 5.3  5.2 5.3  4.6
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; eGFR,
estimated glomerular filtration rate; HbA1c, glycated haemoglobin; SBP, systolic blood pressure; UACR, urinary albumin creatinine ratio. P < .01 with Bon-
ferroni correction between: aonly UACR and good, bpoor and good, cpoor and only SBP, donly SBP and good, eonly SBP and only UACR, fpoor and
only UACR.




−15 to 0 mm Hg
n (%)
Total (%)
0 to 15 mm Hg
n (%)
≥15 mm Hg
n (%) Total (%)
>30% decrease 373 (45.9) 274 (33.7) 647 136 (50.7) 42 (15.7) 178
30% to 0% decrease 95 (11.7) 70 (8.6) 165 62 (23.1) 28 (10.4) 90
Total (%) 468 (57.6) 344 (42.4) 812 (50.8) 198 (73.9) 70 (26.1) 268 (16.8)
0 to 30% increase 77 (21.8) 46 (13.0) 123 38 (22.7) 17 (10.2) 55
≥ 30% increase 138 (39.1) 92 (26.1) 230 74 (44.3) 38 (22.8) 112
Total (%) 215 (60.9) 138 (39.1) 353 (22.1) 112 (67.1) 55 (32.9) 167 (10.4)
Abbreviations: SBP, systolic blood pressure; UACR, urinary albumin creatinine ratio. ΔUACR: difference in UACR between before and after renin angio-
tensin aldosterone system (RAAS) inhibition measurement; ΔSBP: difference in SBP between before and after RAAS inhibition measurement.
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guideline recommendations state that albuminuria response should
not be monitored in adults with or without diabetes.14 According to
the guidelines, the variability in albuminuria may introduce measure-
ment error which may obscure the true variation in response to treat-
ment.14 Indeed, day-to-day variation in SBP and UACR is present in
particular when single measurements are used, as was the case in the
present study. Despite this limitation, however, we were still able to
detect a significant association between UACR and SBP response
and cardiovascular risk, highlighting the importance of monitoring
responses in both variables after RAAS inhibition initiation.
The present study has several strengths. To our knowledge, it is
the first real-life study in primary care assessing variability in response
in SBP and UACR in patients with type 2 diabetes. We performed rig-
orous checks to ensure that only new users of RAAS inhibition treat-
ment were included in the study in order to assess changes in SBP and
UACR after RAAS inhibition. We tried to control for non-adherence to
RAAS inhibition treatment by excluding patients with low levels of
refill adherence during the study period (<75% medication refill adher-
ence or >0.25 continuous measurement of gaps). We do not know,
however, whether the patients actually took the medication they
refilled. Some between-patient variation may be attributable to varia-
tion in medication-taking behaviour. We also excluded patients who
concurrently initiated other antihypertensive treatment. We adjusted
our models for several possible confounders, and conducted stratified
and sensitivity analyses to check for possible biases. In particular, we
found no impact of difference in initial dose or response period; how-
ever, the observational design precludes any causal interpretations.
Limitations of the present study include the fact that a substan-
tial number of patients were excluded because they did not have a
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FIGURE 3 Scatterplot: Correlation
between UACR change and systolic blood
pressure (SBP) change before and after
start of renin angiotensin aldosterone
system inhibition. Histograms: Distribution
of patients according to urinary albumin
creatinine ratio (UACR) change (left) and
SBP change (bottom)






Median (25th to 75th)
Event
n (%)
HR 95% CI P HR 95% CI P
Poor responders
(n = 167)
SBP ≥ 0 mm Hg
/ UACR ≥ 0%
12.1 (12.4) 50.0 (20-125) 23 (13.8) ref ref ref ref ref ref
SBP-only responders
(n = 353)
SBP < 0 mm Hg
/ UACR ≥ 0%
−22.7 (14.9) 46.9 (18-127) 21 (6.0) 0.42 0.23–0.76 0.004 0.48 0.26–0.88 0.018
UACR-only responders
(n = 268)
SBP ≥ 0 mm Hg
/ UACR < 0%
10.0 (10.0) −47.4 (−74 to −23) 30 (11.9) 0.82 0.47–1.41 0.46 0.64 0.36–1.13 0.121
Good responders
(n = 812)
SBP < 0 mm Hg
/ UACR < 0%
−21.9 (15.4) −56.7 (−75 to −35) 54 (6.7) 0.48 0.30–0.78 0.003 0.51 0.30–0.86 0.012
Abbreviations: HR, hazard ratio; SBP, systolic blood pressure; UACR, urinary albumin creatinine ratio.
a Adjusted for sex, baseline age, SBP, logUACR, glycated haemoglobin, diastolic blood pressure, estimated glomerular filtration rate, and cardiovascular
and peripherovascular morbidity.
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short a follow-up. This may have led to selection of patients with
more advanced disease not representative of the general type 2 dia-
betes population treated in Dutch primary practice. However, there
appeared to be no relevant differences in baseline characteristics
between patients included for analysis and all patients who initiated
RAAS inhibition in the GIANTT cohort. Furthermore, the included
patients form a dynamic cohort with variation in time and follow-up
period. Because more intensive monitoring may occur in more dis-
eased patients, this could result in a shorter initial response period
for such patients. We therefore conducted a stratified analysis to see
whether the response groups would differ between patients with a
response period >1 and <1 year, which yielded similar results. Finally,
the response thresholds were somewhat arbitrary. We therefore per-
formed sensitivity analysis for UACR ≥30% reduction from baseline,
and similar results were obtained. Unfortunately, we were unable to
assess the impact of variability in response on mortality.
In conclusion, variability in blood pressure and albuminuria
response after RAAS inhibition initiation occurs between and within
patients with type 2 diabetes in primary care. Patients without
improvement in SBP and UACR were found to have a higher risk of
cardiovascular events than patients with improved SBP and UACR.
Further research is necessary to identify why these patients with
type 2 diabetes do not respond to RAAS inhibition, in order to
develop personalized treatment plans.
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